UPDATE: JP Morgan Downgrades Forest Laboratories to Neutral on Elongated Recovery
JP Morgan downgraded Forest Laboratories (NYSE: FRX) from Overweight to Neutral and lowered its price target from $41 to $37.
JP Morgan said, "While Forest's development efforts have been highly successful and we see meaningful long-term term earnings power for the company, new product launches have lagged our expectations despite a significant ramp in SG&A. With a similar trend potentially repeating itself with several of the company's next-generation product opportunities, we believe Forest could see a more elongated recovery in earnings and along these lines, see better opportunities within our Specialty Pharma coverage."
Forest Laboratories closed at $33.40 on Wednesday.
Latest Ratings for FRX
|Apr 2014||Cantor Fitzgerald||Maintains||Hold|
|Apr 2014||SunTrust Robinson Humphrey||Downgrades||Buy||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.